New bone graft material tested for safer dental implants
NCT ID NCT07179497
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a bone graft material called Neobone® in 66 adults who need dental surgery to rebuild jawbone. The goal is to see if it safely helps regrow enough bone to place a dental implant. Researchers will check bone growth and any side effects over 6 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Neobone® (bone graft material)
- What this could lead to
- If it works, this could provide a safe and effective option for rebuilding jawbone to support dental implants.
- What could go wrong
- This is a small observational study, not a controlled trial, so results may not apply to everyone. There is a risk of infection or the graft not working as expected.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BONE AUGMENTATION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Egas Moniz School of Health and Science Caparica
RECRUITINGLisbon, Portugal
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Hydrogel-Enhanced graft build better bone for dental implants?
- Dissolving magnesium membrane could simplify dental implants
- New study tests stronger membranes for better jawbone building
- New dental bone material put to the test in 80 patients
- Dental implant showdown: titanium mesh vs collagen membrane for stronger smiles
- Fat cells used to regrow jaw bone in first human trial